BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16418689)

  • 21. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
    Ekbal NJ; Holt DW; Macphee IA
    Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
    Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant.
    Almeida-Paulo GN; Dapía García I; Lubomirov R; Borobia AM; Alonso-Sánchez NL; Espinosa L; Carcas-Sansuán AJ
    Pharmacogenomics J; 2018 Jan; 18(1):180-186. PubMed ID: 28094348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
    Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
    Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the clinical pharmacogenomics of organ transplantation.
    Burckart GJ; Amur S
    Pharmacogenomics; 2010 Feb; 11(2):227-36. PubMed ID: 20136361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
    Pharmacogenet Genomics; 2008 Oct; 18(10):861-8. PubMed ID: 18704002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.
    Leroy S; Isapof A; Fargue S; Fakhoury M; Bensman A; Deschênes G; Jacqz-Aigrain E; Ulinski T
    Pediatr Nephrol; 2010 May; 25(5):965-9. PubMed ID: 20091056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.
    Picard N; Marquet P
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):731-43. PubMed ID: 21434840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.
    Lancia P; Adam de Beaumais T; Elie V; Garaix F; Fila M; Nobili F; Ranchin B; Testevuide P; Ulinski T; Zhao W; Deschênes G; Jacqz-Aigrain E
    Pediatr Nephrol; 2018 Jun; 33(6):1045-1055. PubMed ID: 29399716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
    Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
    Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.
    Wang P; Mao Y; Razo J; Zhou X; Wong ST; Patel S; Elliott E; Shea E; Wu AH; Gaber AO
    Pharmacogenomics; 2010 Oct; 11(10):1389-402. PubMed ID: 21047202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practicability of pharmacogenetics in transplantation medicine.
    van Gelder T; van Schaik RH; Hesselink DA
    Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?
    MacPhee IA; Fredericks S; Holt DW
    Expert Opin Pharmacother; 2005 Dec; 6(15):2593-605. PubMed ID: 16316299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.